Applied DNA Sciences Inc. (APDN)
Applied DNA Sciences Statistics
Share Statistics
Applied DNA Sciences has 6.5M shares outstanding. The number of shares has increased by 0.04% in one year.
| Shares Outstanding | 6.5M |
| Shares Change (YoY) | 0.04% |
| Shares Change (QoQ) | 0.79% |
| Owned by Institutions (%) | 0.08% |
| Shares Floating | 6.05M |
| Failed to Deliver (FTD) Shares | 2.87M |
| FTD / Avg. Volume | 250.57% |
Short Selling Information
The latest short interest is 3M, so 46.23% of the outstanding shares have been sold short.
| Short Interest | 3M |
| Short % of Shares Out | 46.23% |
| Short % of Float | 49.62% |
| Short Ratio (days to cover) | 1.63 |
Valuation Ratios
The PE ratio is -18.43 and the forward PE ratio is -0.15. Applied DNA Sciences's PEG ratio is 0.21.
| PE Ratio | -18.43 |
| Forward PE | -0.15 |
| PS Ratio | 37.55 |
| Forward PS | 0.7 |
| PB Ratio | 14.09 |
| P/FCF Ratio | -9.13 |
| PEG Ratio | 0.21 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Applied DNA Sciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.36, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.36 |
| Quick Ratio | 3.17 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | -0.05 |
| Debt / FCF | -0.05 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $74.6K |
| Profits Per Employee | $-152.01K |
| Employee Count | 46 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 5.51 |
Taxes
| Income Tax | 137.3K |
| Effective Tax Rate | -1.94% |
Stock Price Statistics
The stock price has increased by -99.76% in the last 52 weeks. The beta is 0.84, so Applied DNA Sciences's price volatility has been higher than the market average.
| Beta | 0.84 |
| 52-Week Price Change | -99.76% |
| 50-Day Moving Average | 4.9 |
| 200-Day Moving Average | 21.12 |
| Relative Strength Index (RSI) | 19.85 |
| Average Volume (20 Days) | 1.14M |
Income Statement
In the last 12 months, Applied DNA Sciences had revenue of 3.43M and earned -6.99M in profits. Earnings per share was -1.76.
| Revenue | 3.43M |
| Gross Profit | 1.02M |
| Operating Income | -14.02M |
| Net Income | -6.99M |
| EBITDA | -14.02M |
| EBIT | -14.02M |
| Earnings Per Share (EPS) | -1.76 |
Balance Sheet
The company has 6.43M in cash and 739.16K in debt, giving a net cash position of 5.69M.
| Cash & Cash Equivalents | 6.43M |
| Total Debt | 739.16K |
| Net Cash | 5.69M |
| Retained Earnings | -309.67M |
| Total Assets | 15.97M |
| Working Capital | 8.89M |
Cash Flow
In the last 12 months, operating cash flow was -13.71M and capital expenditures -407.9K, giving a free cash flow of -14.12M.
| Operating Cash Flow | -13.71M |
| Capital Expenditures | -407.9K |
| Free Cash Flow | -14.12M |
| FCF Per Share | -3.56 |
Margins
Gross margin is 29.63%, with operating and profit margins of -408.72% and -203.78%.
| Gross Margin | 29.63% |
| Operating Margin | -408.72% |
| Pretax Margin | -206.57% |
| Profit Margin | -203.78% |
| EBITDA Margin | -408.72% |
| EBIT Margin | -408.72% |
| FCF Margin | -411.47% |
Dividends & Yields
APDN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for APDN is $75, which is 8828.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $75 |
| Price Target Difference | 8828.6% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Mar 14, 2025. It was a backward split with a ratio of 1:50.
| Last Split Date | Mar 14, 2025 |
| Split Type | backward |
| Split Ratio | 1:50 |
Scores
| Altman Z-Score | -29.2 |
| Piotroski F-Score | 3 |